BR112015013350A2 - compostos de triazolona e usos dos mesmos - Google Patents

compostos de triazolona e usos dos mesmos

Info

Publication number
BR112015013350A2
BR112015013350A2 BR112015013350A BR112015013350A BR112015013350A2 BR 112015013350 A2 BR112015013350 A2 BR 112015013350A2 BR 112015013350 A BR112015013350 A BR 112015013350A BR 112015013350 A BR112015013350 A BR 112015013350A BR 112015013350 A2 BR112015013350 A2 BR 112015013350A2
Authority
BR
Brazil
Prior art keywords
compounds
melanoma
cancers
colon
breast
Prior art date
Application number
BR112015013350A
Other languages
English (en)
Other versions
BR112015013350B1 (pt
Inventor
Chih-Yu Chen Austin
Andrew Stearns Brian
Duarte Jacintho Jason
Melissa BACCEI Jill
Simon Stock Nicholas
christopher clark Ryan
Mostofi Bravo Yalda
Original Assignee
Inception 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inception 2 Inc filed Critical Inception 2 Inc
Publication of BR112015013350A2 publication Critical patent/BR112015013350A2/pt
Publication of BR112015013350B1 publication Critical patent/BR112015013350B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

“compostos de triazolona e usos dos mesmos” resumo a invenção divulgada aqui é direcionada a compostos da fórmula i i e sais farmaceuticamente aceitáveis dos mesmos, que são úteis no tratamento de câncer de próstata, mama, cólon, pancreático, leucemia linfocítica crônica humana, melanoma e outros cânceres. a invenção compreende ainda composições farmacêuticas que compreendem uma quantidade terapeuticamente eficiente de composto da fórmula i ou um sal farmaceuticamente aceitável do mesmo. a invenção divulgada aqui também se direciona a processos de tratamento de câncer de próstata, mama, ovariano, fígado, rim, cólon, pancreático, leucemia linfocítica crônica humana, melanoma e outros cânceres. a invenção divulgada aqui é adicionalmente direcionada a processos de tratamento de câncer de próstata, mama, cólon, pancreático, leucemia linfocítica crônica, melanoma e outros cânceres que compreendem a administração de uma quantidade terapeuticamente eficiente de um antagonista de ppar? seletivo. os compostos e as composições farmacêuticas da invenção também são úteis no tratamento de infecções virais, tais como infecções com hcv e infecções com hiv. 1/1
BR112015013350-9A 2012-12-20 2013-12-10 Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos BR112015013350B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739906P 2012-12-20 2012-12-20
US61/739,906 2012-12-20
PCT/US2013/074197 WO2014099503A1 (en) 2012-12-20 2013-12-10 Triazolone compounds and uses thereof

Publications (2)

Publication Number Publication Date
BR112015013350A2 true BR112015013350A2 (pt) 2017-07-11
BR112015013350B1 BR112015013350B1 (pt) 2022-04-05

Family

ID=50979036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013350-9A BR112015013350B1 (pt) 2012-12-20 2013-12-10 Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos

Country Status (18)

Country Link
US (4) US9676754B2 (pt)
EP (1) EP2935228B9 (pt)
JP (1) JP6404230B2 (pt)
KR (1) KR102300675B1 (pt)
CN (1) CN104918922B (pt)
AU (1) AU2013363398B2 (pt)
BR (1) BR112015013350B1 (pt)
CA (1) CA2894281C (pt)
DK (1) DK2935228T3 (pt)
EA (1) EA027986B9 (pt)
ES (1) ES2660249T3 (pt)
HK (1) HK1212680A1 (pt)
IL (1) IL239372B (pt)
MX (1) MX2015007433A (pt)
NO (1) NO3003327T3 (pt)
PE (1) PE20151521A1 (pt)
SG (1) SG11201504622PA (pt)
WO (1) WO2014099503A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
PE20160880A1 (es) * 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
WO2022052982A1 (zh) * 2020-09-14 2022-03-17 昭明泽康（北京）生物医药科技有限公司 PPARα（过氧化物酶体增殖物激活受体α）配体在制备药物中的应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE160447C (pt)
NL189197C (nl) 1979-09-04 1993-02-01 Bristol Myers Squibb Co 3,4-digesubstitueerde-1,2,5-thiadiazool-1-oxiden en 1,1-dioxiden, bereiding daarvan alsmede farmaceutische preparaten.
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
IN158869B (pt) 1981-03-18 1987-02-07 Ici Plc
DD160447A1 (de) 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
DE3267110D1 (de) 1981-05-18 1985-12-05 Ici Plc Amidine derivatives
DE3238590A1 (de) 1982-10-19 1984-04-19 VEB Fahlberg-List Chemische und pharmazeutische Fabriken, DDR 3013 Magdeburg Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
NL8204109A (nl) 1982-10-25 1984-05-16 Fahlberg List Veb Herbicide middelen, die 1.2.4-triazolinon-(5)-verbindingen bevatten.
BE894856A (fr) 1982-10-28 1983-02-14 Fahlberg List Veb Compositions herbicides a base d'un derive de la 1,2,4-triazolinone-(5)
FR2535168B1 (fr) 1982-10-29 1985-08-09 Fahlberg List Veb Agents herbicides a base de 1, 2, 4-triazolinone 5
JPS60215675A (ja) 1984-04-09 1985-10-29 Nippon Nohyaku Co Ltd オキサジアゾリノン誘導体及びトリアゾリノン誘導体並びにその製造方法並びに昆虫成長制御剤
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
WO1992004346A1 (en) 1990-09-06 1992-03-19 Pfizer Limited Antimuscarinic bronchodilators
JP2772875B2 (ja) 1991-05-14 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物
PT612314E (pt) 1991-10-30 2000-06-30 Astra Ab Derivados de etilamina 2-heterociclicos e seu uso como produtos farmaceuticos
WO1993021181A1 (en) 1992-04-15 1993-10-28 Merck Sharp & Dohme Limited Azacyclic compounds
DE4224929A1 (de) 1992-07-28 1994-02-03 Bayer Ag Heterocyclyltriazolinone
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
IT1256387B (it) 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE4343595A1 (de) 1993-12-21 1995-06-22 Bayer Ag Verfahren zur Herstellung von Sulfonylaminocarbonyltriazolinonen
US5550118A (en) 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
DE4404848A1 (de) 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
JPH08157473A (ja) 1994-10-06 1996-06-18 Nissan Chem Ind Ltd ピラゾール系チアゾリジン類
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
IN183333B (pt) 1995-03-15 1999-11-20 Indian Drugs & Pharma
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
EP0784053A1 (de) 1996-01-15 1997-07-16 Degussa Aktiengesellschaft Verfahren zur Herstellung von Triazolinonherbiziden
DE19601189A1 (de) 1996-01-15 1997-07-17 Degussa Verfahren zur Herstellung von 1,2,4-Triazolin-3(2H)-onen
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
JP2001502311A (ja) 1996-10-07 2001-02-20 メルク シヤープ エンド ドーム リミテツド 抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬
ATE314097T1 (de) 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1999003835A1 (fr) 1997-07-18 1999-01-28 Nippon Kayaku Kabushiki Kaisha Derives cetoniques aromatiques et leurs utilisations
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
KR20010052488A (ko) 1998-06-03 2001-06-25 쥐피아이 엔아이엘 홀딩스 인코포레이티드 신경계 질환 및 탈모 치료에 사용되는 아자-헤테로고리화합물
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
CN1295561A (zh) 1998-06-03 2001-05-16 Gpinil控股公司 N－杂环羧酸或羧酸等排物的n－结合氨磺酰
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
AU5477899A (en) 1998-08-14 2000-03-06 Gpi Nil Holdings, Inc. Ureas and carbamates of N-heterocyclic carboxylic acids and isosteres for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
SE9802937D0 (sv) 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
WO2000029386A1 (en) 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
DE19955662B4 (de) 1999-11-19 2011-03-31 Arysta LifeScience North America, Herbizide auf Basis von Carbamoyltriazolinon
EP1110958A1 (en) 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU6594401A (en) 2000-05-24 2001-12-03 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
CA2469821C (en) 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
ES2311711T3 (es) 2002-02-07 2009-02-16 The Curators Of The University Of Missouri Compuestos de 4-(3-hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos como receptores de opioides.
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
EP1513829A2 (en) 2002-06-14 2005-03-16 Syngenta Participations AG Nicotinoyl derivatives as herbicidal compounds
AU2003284001A1 (en) 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
JP2006502230A (ja) 2002-10-11 2006-01-19 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
BR0315247A (pt) 2002-10-11 2005-08-30 Cytokinetics Inc Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
US7268151B2 (en) 2003-04-04 2007-09-11 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077178A2 (en) 2004-02-16 2005-08-25 Syngenta Participations Ag Herbicidal composition
AU2005214375A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
RU2394028C2 (ru) 2004-07-27 2010-07-10 Ф.Хоффманн-Ля Рош Аг Производные бензилтриазолона в качестве ненуклеозидных ингибиторов обратной транскриптазы
CN1315810C (zh) 2004-08-30 2007-05-16 北京理工大学 哌嗪桥联他克林双体衍生物及其合成方法
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
AU2006205850A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
PE20061041A1 (es) 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
AU2006235706B2 (en) 2005-04-12 2012-03-08 Vicore Pharma Ab New tricyclic angiotensin II agonists
DE112006001089B4 (de) 2005-04-28 2015-05-28 Denso Corporation Mehrphasiger bürstenloser Elektromotor
DE102005025992A1 (de) 2005-06-07 2007-01-11 Lanxess Deutschland Gmbh Verfahren zur Herstellung von substituierten Azolen
US20070032488A1 (en) 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
DE102006003444A1 (de) 2006-01-25 2007-07-26 Lanxess Deutschland Gmbh Verfahren zur Herstellung von iodierten Azolen
GB2435827A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
GB2435829A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
GB2435828A (en) 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
MX2008011857A (es) 2006-03-23 2008-12-15 Prolysis Ltd Agentes antibacterianos.
AU2007230346B2 (en) 2006-03-24 2011-12-22 Eisai R & D Management Co., Ltd. Triazolone derivative
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
JP5441690B2 (ja) 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
DE102006032164A1 (de) 2006-07-12 2008-01-24 Bayer Cropscience Ag Substituierte Furyl-sulfonylamino(thio)carbonyl-triazolin(thi)one
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
CN101535303B (zh) 2006-08-15 2012-07-18 诺瓦提斯公司 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物
US20100099725A1 (en) 2007-02-23 2010-04-22 Lance Allen Pfeifer Peroxisome proliferator activated receptor modulators
JP2010522706A (ja) 2007-03-29 2010-07-08 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤
EP2148878A4 (en) 2007-04-20 2011-08-10 Merck Canada Inc NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
US8119693B2 (en) 2007-05-08 2012-02-21 Sanford-Burnham Medical Research Institute Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
ES2617305T3 (es) 2007-07-17 2017-06-16 Acea Biosciences, Inc. Compuestos heterocíclicos y usos como agentes anticancerosos
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
US8222254B2 (en) 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
AU2008334489A1 (en) 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
NZ589617A (en) 2008-05-14 2012-06-29 Scripps Research Inst 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives
ES2423793T3 (es) 2008-05-26 2013-09-24 Genfit Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US7943796B2 (en) * 2008-07-31 2011-05-17 Chevron Oronise Company LLC Lubricating oil additive and lubricating oil composition containing same
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
JP2011231015A (ja) 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
KR20110082145A (ko) 2008-10-21 2011-07-18 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１２０ 수용체 작동약 및 이의 용도
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
WO2010139966A1 (en) 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors
WO2011005595A2 (en) 2009-06-24 2011-01-13 Alios Biopharma, Inc. 2-5a analogs and their methods of use
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011058478A1 (en) 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
KR101169359B1 (ko) 2010-01-29 2012-07-30 주식회사 레고켐 바이오사이언스 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
EP2538787B1 (en) 2010-02-22 2014-07-16 GlaxoSmithKline LLC Triazolones as fatty acid synthase inhibitors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
EP2371823A1 (de) 2010-04-01 2011-10-05 Bayer CropScience AG Cyclopropyl-substituierte Phenylsulfonylamino(thio)carbonyltriazolinone, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US20130158063A1 (en) 2010-08-24 2013-06-20 Georgetown University Compounds, Compositions and Methods Related to PPAR Antagonists
WO2012037299A2 (en) * 2010-09-17 2012-03-22 Glaxosmithkline Llc Fatty acid synthase inhibitors
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos

Also Published As

Publication number Publication date
SG11201504622PA (en) 2015-07-30
CA2894281A1 (en) 2014-06-26
ES2660249T3 (es) 2018-03-21
DK2935228T3 (en) 2017-10-30
EP2935228A4 (en) 2016-05-04
MX2015007433A (es) 2015-12-07
CN104918922A (zh) 2015-09-16
IL239372B (en) 2018-08-30
EP2935228A1 (en) 2015-10-28
US20150344446A1 (en) 2015-12-03
EP2935228B1 (en) 2017-08-02
KR20150099537A (ko) 2015-08-31
WO2014099503A1 (en) 2014-06-26
AU2013363398A1 (en) 2015-07-23
IL239372A0 (en) 2015-07-30
EA027986B9 (ru) 2018-01-31
US11666557B2 (en) 2023-06-06
KR102300675B1 (ko) 2021-09-13
AU2013363398B2 (en) 2017-06-01
EP2935228B9 (en) 2017-12-06
PE20151521A1 (es) 2015-11-25
NO3003327T3 (pt) 2018-01-06
HK1212680A1 (zh) 2016-06-17
US20170239223A1 (en) 2017-08-24
CN104918922B (zh) 2017-04-26
EA027986B1 (ru) 2017-09-29
US10568871B2 (en) 2020-02-25
JP2016508132A (ja) 2016-03-17
CA2894281C (en) 2021-04-20
EA201590909A1 (ru) 2015-12-30
BR112015013350B1 (pt) 2022-04-05
US9676754B2 (en) 2017-06-13
JP6404230B2 (ja) 2018-10-10
US20200138790A1 (en) 2020-05-07
US20240041837A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
BR112016017781A2 (pt) Compostos de pirazolona e usos dos mesmos
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
CY1119714T1 (el) Ενωσεις αναστολεων
BR112018001650A2 (pt) compostos de heteroarila ou arila fundidos bicíclicos como moduladores de irak4
BR112012018413A2 (pt) 1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos.
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112016030787A8 (pt) entidade química, composição farmacêutica e seu uso
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
BR112015018509A2 (pt) compostos de imidazo piridina
EA201201159A1 (ru) Дейтерированные соединения пирролопиримидина в качестве ингибиторов cdk4/6
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
BR112018074961A2 (pt) derivados de nucleosídeo de fosforamidato como agentes anticâncer
BR112015006436A2 (pt) novas piridinonas bicíclicas
PH12018502473A1 (en) Pegylated carfilzomib compounds
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
EA201591024A1 (ru) Димерные соединения
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TEMPEST THERAPEUTICS, INC. (US)

B25G Requested change of headquarter approved

Owner name: TEMPEST THERAPEUTICS, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/12/2013, OBSERVADAS AS CONDICOES LEGAIS.